dapagliflozin
astrazeneca
['cardio']
 #deliver trial question sglti vs placebo in hfpef 6,263 hfpef pts. f/u 2.3 years outcome: cv death or worsening hf #sglti cv death &amp; hf worsening. #sglti beneficial across all #lvef &amp; subgroups #esccongress #esc2022 #esc22 #medtwitter #cardiotwitter 
Cardiology Fellow @OHSUCardio| MSc in Clinical Trials @Oxford_NDPH '23 | MPH @Harvard | Postdoc @UPMC | ABIM @HenryFord. #ESCCongress #Medtwitter #ESCGuidelines